VistaGen Therapeutics Acquires WW Rights for Pherin's PH94B nasal spray for the Treatment of Social Anxiety Disorder
Shots:
- Pherin will receive $2.25M of unregistered common stock (1-630-435 unregistered shares) from Vista
- VistaGen has rights to commercialize and develop PH94B nasal spray (expected to enter in P-III in H1’19) as a PRN treatment for SAD- in addition to an option to acquire Pherin’s CNS neuropsychiatry-focused product currently under P-II
- The main focus of this agreement is to continue clinical trials for PH94B- showing its tolerance with no AEs & making an advancement in novel treatments for the patients affected with SAD. PH94B patents has been granted in the US- EU- Japan- China- Korea and other countries
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
